المؤلفون: Ikchan Jeon, Sung Bae Park, Bong Ju Moon, Miyoung Choi, Sung Uk Kuh, Jongtae Kim

المصدر: Neurospine, Vol 21, Iss 2, Pp 416-429 (2024)

مصطلحات موضوعية: teriparatide, romosozumab, bisphosphonate, osteoporosis, vertebral fracture, meta-analysis, Neurology. Diseases of the nervous system, RC346-429

الوصف: Objective We investigated the clinical efficacy of anabolic agents compared with bisphosphonates (BPs) for the incidence of new osteoporotic vertebral fracture (OVF) and fracture healing of OVF in the patients with OVF via meta-analyses of randomized controlled trials (RCTs). Methods Electronic databases, including PubMed, Embase, and Cochrane Library were searched for published RCTs till December 2022. The RCTs that recruited participants with osteoporosis at high-/very high-risk of fracture (a history of osteoporotic vertebral or hip fracture) or fresh OVF were included in this study. We assessed the risk of bias on every included RCTs, estimated relative risk (RR) for the incidence of new OVF and fracture healing of OVF, and overall certainty of evidence. Meta-analyses were performed by Cochrane review manager (RevMan) ver. 5.3. Cochrane risk of bias 2.0 and GRADEpro/GDT were applied for evaluating methodological quality and overall certainty of evidence, respectively. Results Five hundred eighteen studies were screened, and finally 6 eligible RCTs were included in the analysis. In the patients with prevalent OVF, anabolic agents significantly reduced the incidence of new OVF (teriparatide and romosozumab vs. alendronate and risedronate [RR, 0.57; 95% confidence interval, 0.45–0.71; p < 0.00001; high-certainty of evidence]; teriparatide vs. risedronate [RR, 0.50; 95% confidence interval, 0.37–0.68; p < 0.0001; high-certainty of evidence]). However, there was no evidence of teriparatide compared to alendronate in fracture healing of OVF (RR, 1.23; 95% confidence interval, 0.95–1.60; p = 0.12; low-certainty of evidence). Conclusion In the patients with prevalent OVF, anabolic agents showed a significant superiority for preventing new OVF than BPs, with no significant evidence for promoting fracture healing of OVF. However, considering small number of RCTs in this study, additional studies with large-scale data are required to obtain more robust evidences.

وصف الملف: electronic resource

العلاقة: http://e-neurospine.org/upload/pdf/ns-2347256-628.pdfTest; https://doaj.org/toc/2586-6583Test; https://doaj.org/toc/2586-6591Test

الوصول الحر: https://doaj.org/article/0c1bb19a390943aa9909f2d34b99d744Test

المؤلفون: Maria L.R. Defante, Victoria Alzogaray, Davi Said Gonçalves Celso, Lucas Antônio Torres, Mayara Bearse, Ana Claudia Frota Machado de Melo Lopes

المصدر: Osteoporosis and Sarcopenia, Vol 10, Iss 2, Pp 47-53 (2024)

مصطلحات موضوعية: Osteoporosis, Renal insufficiency, Monoclonal antibodies, Denosumab, Romosozumab, Diseases of the musculoskeletal system, RC925-935

الوصف: Objectives: There are challenges for the treatment of osteoporosis in patients with kidney failure and monoclonal antibodies (MAb) might be a suitable therapy. However, the efficacy and safety of MAb among patients with osteoporosis and renal insufficiency remains unclear. Methods: We systematically searched PubMed, Embase, and Cochrane Central for studies evaluating the efficacy and safety of the use of MAb in patients with osteoporosis and renal insufficiency. We pooled risk ratios (RR) and 95% confidence intervals (CI) for binary outcomes. Mean difference (MD) was used for continuous outcomes. Results: We included 5 studies with 33,550 patients. MAb therapy decreased the risk of vertebral fractures (RR 0.32; 95% CI 0.26–0.40; P

وصف الملف: electronic resource

العلاقة: http://www.sciencedirect.com/science/article/pii/S2405525524000669Test; https://doaj.org/toc/2405-5255Test

الوصول الحر: https://doaj.org/article/4cdc8db900864c718a882c9d9484ca67Test

المؤلفون: Keishi Maruo, Tomoyuki Kusukawa, Masakazu Toi, Tetsuto Yamaura, Masaru Hatano, Hayato Oishi, Kazuma Nagao, Fumihiro Arizumi, Kazuya Kishima, Norichika Yoshie, Toshiya Tachibana

المصدر: Bone Reports, Vol 21, Iss , Pp 101762- (2024)

مصطلحات موضوعية: Domino osteoporotic vertebral fracture, Osteoanabolic agent, Teriparatide, Romosozumab, Diseases of the musculoskeletal system, RC925-935

الوصف: Introduction: Domino osteoporotic vertebral fracture (OVF) is as a subsequent fracture that develops within 3 months before the initial OVF heals. There is limited evidence regarding the efficacy of osteoanabolic agents on its treatment. This study evaluated the effects of bisphosphonates and anabolic agents teriparatide and romosozumab on subsequent domino OVF. Methods: This was post hoc analysis of a prospective, multicenter, observational study conducted across 8 hospitals, enrolling 144 patients with conservatively treated OVF, grouped into patients receiving bisphosphonate (BP, n = 55), teriparatide (TPTD, n = 62), and romosozumab (Romo, n = 27). The primary outcome was the incidence of subsequent OVF at 3 and 12 months, whereas the secondary outcomes included the incidence of pseudoarthrosis and progression of vertebral collapse (VC). Pseudoarthrosis was classified as stable or unstable based on vertebral instability. Results: The use of osteoanabolic agents did not reduce the incidence of subsequent OVF at 3 and 12 months. There were no significant differences in the background data or type of conservative treatment among the three groups. However, the TPTD and Romo groups had significantly lower rates of unstable pseudarthrosis (p = 0.03). Additionally, there were no significant differences in VC progression between groups, but it tended to be higher in the BP group than the TPTD and Romo group (p = 0.07). Conclusion: Osteoanabolic agents were beneficial in reducing unstable pseudoarthrosis, but were not more effective than bisphosphonates in the development of subsequent domino OVF. A more comprehensive approach to the treatment of osteoporosis is needed to prevent domino OVFs.

وصف الملف: electronic resource

العلاقة: http://www.sciencedirect.com/science/article/pii/S2352187224000299Test; https://doaj.org/toc/2352-1872Test

الوصول الحر: https://doaj.org/article/60a35d12b45c44279c2b331e34e3ae6bTest

المؤلفون: Danbi Park, Seo Eun Kim, Hong Kyung Shin, Junghan Seo, Jeong Kyun Joo, Chongman Kim, Sang Hyub Lee, Jin Hoon Park

المصدر: Neurospine, Vol 20, Iss 4, Pp 1217-1223 (2023)

مصطلحات موضوعية: romosozumab, teriparatide, bone mineral density, osteoporosis, osteoporotic vertebral compression fracture, vertebral compression fracture, Neurology. Diseases of the nervous system, RC346-429

الوصف: Objective Romosozumab is increasingly employed to manage osteoporosis. However, no studies have analyzed its effects on recent osteoporotic vertebral compression fractures (OVCFs). Therefore, this study aimed to evaluate the efficacy of romosozumab compared with teriparatide in managing OVCFs. Methods The electronic medical records of postmenopausal patients with recent OVCFs who were administered romosozumab or teriparatide for one year from March 2018 to August 2022 were retrospectively reviewed. We compared the 2 groups for demographics, radiological outcomes (compression ratio, Cobb angle, and bone mineral density [BMD]), and clinical outcomes (Numerical Rating Scale [NRS] for back pain). Results Fifty-five patients with OVCFs, 32 patients treated with romosozumab and 23 with teriparatide, were included in this study. The change of BMD (g/cm2) values was significantly higher (p = 0.016) in the romosozumab (0.04 ± 0.06) than in the teriparatide group (0.00 ± 0.08) in the femur total. Furthermore, in subgroup analysis, the change of BMD (g/cm2) values in the lumbar spine was significantly higher (p = 0.016) in the romosozumab (0.12 ± 0.06) than in the teriparatide group (0.07 ± 0.06) in the lumbar spine. The decrease in NRS was significantly higher (p = 0.013) in the romosozumab (6.6 ± 2.0) than in the teriparatide group (5.5 ± 2.1). However, there was no significant difference in radiologic outcomes between the 2 groups. Conclusion Our findings suggest that romosozumab may be more effective than teriparatide in treating OVCFs in postmenopausal females, particularly in improving BMD and reducing back pain as measured by NRS.

وصف الملف: electronic resource

العلاقة: http://e-neurospine.org/upload/pdf/ns-2347030-515.pdfTest; https://doaj.org/toc/2586-6583Test; https://doaj.org/toc/2586-6591Test

الوصول الحر: https://doaj.org/article/ef3fa1d33b834e45b3803c2e6b133143Test

المؤلفون: Antara Dattagupta, MD, MEng, Steven Petak, MD, JD

المصدر: AACE Clinical Case Reports, Vol 9, Iss 6, Pp 209-212 (2023)

مصطلحات موضوعية: osteogenesis imperfecta, romosozumab, bone mineral density, Diseases of the endocrine glands. Clinical endocrinology, RC648-665

الوصف: Background/Objective: Osteogenesis imperfecta (OI) is a genetic disorder that affects type 1 collagen synthesis causing increased bone fragility, low bone mass, and skeletal deformity. Bisphosphonates are recommended for treatment of OI patients; however, the efficacy of sclerostin inhibitors such as romosozumab has not been determined in OI patients with osteoporosis. Case Report: A 52-year-old G2P2 clinically diagnosed with OI, with a history of multiple fractures beginning in childhood presented with low bone mass. On physical examination, blue sclera was observed. She was previously treated with alendronate therapy from April 2014 to June 2015 without significant improvement in bone mineral density (BMD). After the onset of menopause, she began romosozumab 210 mg subcutaneous therapy once a month for 12 months. Repeat dual-energy X-ray absorptiometry showed an increase of 10.3% in BMD of the spine and a 5.4% increase in BMD of the right hip. The trabecular bone score increased by 5.2%. Discussion: Current literature is limited regarding the use of sclerostin inhibitors in OI patients. Our patient’s improvement in BMD of the spine and right hip after romosozumab therapy was significant at a 95% confidence level, compared to treatment initiation. Her trabecular bone score also improved significantly. Six months into our patient’s treatment course, a case in Japan of a male with severe osteoporotic OI and recurrent fractures showed improvement in BMD after romosozumab therapy. Conclusion: This case highlights our patient’s significant response to romosozumab and warrants further investigation of romosozumab as a potential treatment option for OI patients with osteoporosis.

وصف الملف: electronic resource

العلاقة: http://www.sciencedirect.com/science/article/pii/S2376060523001438Test; https://doaj.org/toc/2376-0605Test

الوصول الحر: https://doaj.org/article/57fb4b24a2d94c65b119f3a0d7b4fae8Test

المؤلفون: Matthias Tröltzsch

المصدر: Frontiers in Immunology, Vol 15 (2024)

مصطلحات موضوعية: immunology, periodontitis, MRONJ, dry socket (alveolitis osteitis), periimplantitis, romosozumab, Immunologic diseases. Allergy, RC581-607

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/articles/10.3389/fimmu.2024.1394835/fullTest; https://doaj.org/toc/1664-3224Test

الوصول الحر: https://doaj.org/article/2855def93bb44e9eb16d3e3ccd098183Test

المؤلفون: Maria Eleni Chondrogianni, Ioannis Kyrou, Theodoros Androutsakos, Christina-Maria Flessa, Evangelos Menenakos, Kamaljit Kaur Chatha, Yekaterina Aranan, Athanasios G. Papavassiliou, Eva Kassi, Harpal S. Randeva

المصدر: Frontiers in Endocrinology, Vol 15 (2024)

مصطلحات موضوعية: anti-osteoporotic drugs, non-alcoholic fatty liver disease, denosumab, romosozumab, bisphosphonates, calcitonin, Diseases of the endocrine glands. Clinical endocrinology, RC648-665

الوصف: Over the last years non-alcoholic fatty liver disease (NAFLD) has grown into the most common chronic liver disease globally, affecting 17-38% of the general population and 50-75% of patients with obesity and/or type 2 diabetes mellitus (T2DM). NAFLD encompasses a spectrum of chronic liver diseases, ranging from simple steatosis (non-alcoholic fatty liver, NAFL) and non-alcoholic steatohepatitis (NASH; or metabolic dysfunction-associated steatohepatitis, MASH) to fibrosis and cirrhosis with liver failure or/and hepatocellular carcinoma. Due to its increasing prevalence and associated morbidity and mortality, the disease-related and broader socioeconomic burden of NAFLD is substantial. Of note, currently there is no globally approved pharmacotherapy for NAFLD. Similar to NAFLD, osteoporosis constitutes also a silent disease, until an osteoporotic fracture occurs, which poses a markedly significant disease and socioeconomic burden. Increasing emerging data have recently highlighted links between NAFLD and osteoporosis, linking the pathogenesis of NAFLD with the process of bone remodeling. However, clinical studies are still limited demonstrating this associative relationship, while more evidence is needed towards discovering potential causative links. Since these two chronic diseases frequently co-exist, there are data suggesting that anti-osteoporosis treatments may affect NAFLD progression by impacting on its pathogenetic mechanisms. In the present review, we present on overview of the current understanding of the liver-bone cross talk and summarize the experimental and clinical evidence correlating NAFLD and osteoporosis, focusing on the possible effects of anti-osteoporotic drugs on NAFLD.

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/articles/10.3389/fendo.2024.1344376/fullTest; https://doaj.org/toc/1664-2392Test

الوصول الحر: https://doaj.org/article/d54d91e4eda24e93a32373a2a96b04d4Test

المؤلفون: Bhanvi Ramchandani, Faryal Sardar Mirza

المصدر: Bone Reports, Vol 20, Iss , Pp 101736- (2024)

مصطلحات موضوعية: Post-menopausal osteoporosis, Romosozumab, Primary biliary cholangitis, Fractures, Monoclonal antibodies, Diseases of the musculoskeletal system, RC925-935

الوصف: Romosozumab (RSB) is a monoclonal antibody to sclerostin that is approved for post-menopausal osteoporosis at high fracture risk. It is administered as a monthly 210 mg subcutaneous injection for 12 months. We report the response to half the standard dose of RSB in an underweight patient with severe osteoporosis and primary biliary cholangitis (PBC). Using half dose RSB (approximately 3 mg/kg RSB), she demonstrated significant improvement in lumbar spine BMD, paralleling the results of phase III trials. This case highlights the effectiveness of RSB in a patient with concomitant PBC, in addition to its effectiveness at half the recommended dose in an underweight patient.

وصف الملف: electronic resource

العلاقة: http://www.sciencedirect.com/science/article/pii/S2352187224000032Test; https://doaj.org/toc/2352-1872Test

الوصول الحر: https://doaj.org/article/96e82a61061a41108915e8f129f41fe8Test

المؤلفون: Dong Wu, Lei Li, Zhun Wen, Guangbin Wang

المصدر: Journal of Translational Medicine, Vol 21, Iss 1, Pp 1-13 (2023)

مصطلحات موضوعية: Romosozumab, Osteoporosis, Wnt/β-catenin signaling pathway, Sclerostin, Medicine

الوصف: Abstract Osteoporosis is a systemic bone disease characterized by low bone mass, microarchitectural deterioration, increased bone fragility, and fracture susceptibility. It commonly occurs in older people, especially postmenopausal women. As global ageing increases, osteoporosis has become a global burden. There are a number of medications available for the treatment of osteoporosis, categorized as anabolic and anti-resorptive. Unfortunately, there is no drugs which have dual influence on bone, while all drugs have limitations and adverse events. Some serious adverse events include jaw osteonecrosis and atypical femoral fracture. Recently, a novel medication has appeared that challenges this pattern. Romosozumab is a novel drug monoclonal antibody to sclerostin encoded by the SOST gene. It has been used in Japan since 2019 and has achieved promising results in treating osteoporosis. However, it is also accompanied by some controversy. While it promotes rapid bone growth, it may cause serious adverse events such as cardiovascular diseases. There has been scepticism about the drug since its inception. Therefore, the present review comprehensively covered romosozumab from its inception to its clinical application, from animal studies to human studies, and from safety to cost. We hope to provide a better understanding of romosozumab for its clinical application.

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/1479-5876Test

الوصول الحر: https://doaj.org/article/1494b6e3f0dc4b369081f0bd6ce195e1Test

المؤلفون: 仲宗根 哲, 伊藝 尚弘, 翁長 正道, 西田 康太郎, 譜久山 倫子, 鷲﨑 郁之

المصدر: 整形外科と災害外科 / Orthopedics & Traumatology. 2023, 72(4):686